VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
GKOSGlaukos Corporation
$130.68$7.6B
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist

GKOS logoGlaukos Corporation(GKOS)Earnings, Financials & Key Ratios

GKOS•NYSE
Price updated Jun 19, 2026
SectorHealthcareIndustryMedical DevicesSub-IndustryVision, dental, and ENT devices
AboutGlaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.Show more
  • Revenue$507M+32.3%
  • EBITDA-$44M+46.2%
  • Net Income-$188M-28.2%
  • EPS (Diluted)-3.28-18.4%
  • Gross Margin77.49%+2.7%
  • EBITDA Margin-8.75%+59.3%
  • Operating Margin-17.09%+46.4%
  • Net Margin-36.99%+3.1%
  • ROE-26.38%-10.7%

GKOS Key Insights

Glaukos Corporation (GKOS) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

  • ✓Strong 5Y sales CAGR of 17.7%

✗Weaknesses

  • ✗Weak Piotroski F-Score: 3/9
  • ✗Negative free cash flow
  • ✗Low quality earnings: Net income not backed by cash flow
  • ✗Expensive at 11.4x book value

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Get notified when GKOS posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

GKOS Price & Volume

Glaukos Corporation (GKOS) stock price & volume — 10-year historical chart

Loading chart...

GKOS Growth Metrics

Glaukos Corporation (GKOS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years21.61%
5 Years17.67%
3 Years21.51%
TTM36.3%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-53.08%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM-38.4%

Return on Capital

10 Years-8.03%
5 Years-9.82%
3 Years-12.63%
Last Year-10.25%

GKOS Recent Earnings

Glaukos Corporation (GKOS) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 11/12 qtrs (92%)
Q2 2026Latest
Apr 29, 2026
Metric
Actual
Est
EPS
$0.18+40.0%
$0.30
Rev
$151M+9.9%
$137M
Q1 2026
Feb 17, 2026
Metric
Actual
Est
EPS
$0.28-27.3%
$0.22
Rev
$143M+4.9%
$136M
Q4 2025
Oct 29, 2025
Metric
Actual
Est
EPS
$0.16+40.7%
$0.27
Rev
$134M+3.2%
$129M
Q3 2025
Jul 30, 2025
Metric
Actual
Est
EPS
$0.24+7.7%
$0.26
Rev
$124M+1.4%
$122M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestApr 29, 2026
$0.18vs $0.30+40.0%
$151Mvs $137M+9.9%
Q1 2026Feb 17, 2026
$0.28vs $0.22-27.3%
$143Mvs $136M+4.9%
Q4 2025Oct 29, 2025
$0.16vs $0.27+40.7%
$134Mvs $129M+3.2%
Q3 2025Jul 30, 2025
$0.24vs $0.26+7.7%
$124Mvs $122M+1.4%
Based on last 12 quarters of dataView full earnings history →

GKOS Peer Comparison

Glaukos Corporation (GKOS) competitors in Vision, dental, and ENT devices — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
Institutional Holdings
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
ATRC logoATRCAtriCure, Inc.Direct Competitor1.46B28.80-12014.88%-0.83%-0.95%0.18
NVCR logoNVCRNovoCure LimitedDirect Competitor1.62B14.28-11.708.28%-25.66%-50.82%0.85
TNDM logoTNDMTandem Diabetes Care, Inc.Direct Competitor1.05B15.30-5.037.93%-9.2%-68.29%2.86
INSP logoINSPInspire Medical Systems, Inc.Direct Competitor1.23B42.618.7113.6%14.33%17.98%0.04
EW logoEWEdwards Lifesciences CorporationProduct Competitor50.37B87.3647.7411.55%17.64%10.35%0.07
ALGN logoALGNAlign Technology, Inc.Product Competitor13.04B182.0832.230.9%10.5%10.7%0.03
HOLX logoHOLXHologic, Inc.Product Competitor16.97B76.0130.531.74%13.18%11.01%0.52
IRTC logoIRTCiRhythm Technologies, Inc.Product Competitor3.44B104.65-75.2926.24%-3.53%-20.6%4.79

Compare GKOS vs Peers

Glaukos Corporation (GKOS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ATRC

Most directly comparable listed peer for GKOS.

Scale Benchmark

vs ABT

Larger-name benchmark to compare GKOS against a more recognizable public peer.

Peer Set

Compare Top 5

vs ATRC, NVCR, TNDM, INSP

GKOS Income Statement

Glaukos Corporation (GKOS) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Sales/Revenue
159.25M181.28M236.98M224.96M294.01M282.86M314.71M383.48M507.44M551.35M
Revenue Growth %
39.21%13.83%30.73%-5.07%30.7%-3.79%11.26%21.85%32.33%36.3%
Cost of Goods Sold
21.05M25.07M38.59M91.72M66.63M68.98M75.58M94.03M114.23M120.84M
COGS % of Revenue
13.22%13.83%16.28%40.77%22.66%24.39%24.01%24.52%22.51%-
Gross Profit
138.2M▲ 0%
156.2M▲ 13.0%
198.4M▲ 27.0%
133.24M▼ 32.8%
227.38M▲ 70.7%
213.88M▼ 5.9%
239.14M▲ 11.8%
289.45M▲ 21.0%
393.22M▲ 35.8%
430.51M▲ 0%
Gross Margin %
86.78%86.17%83.72%59.23%77.34%75.61%75.99%75.48%77.49%78.08%
Gross Profit Growth %
40.71%13.02%27.01%-32.84%70.66%-5.94%11.81%21.04%35.85%-
Operating Expenses
140.49M169.21M248.69M256.79M260.26M296.2M367.84M411.82M479.95M516.42M
OpEx % of Revenue
88.21%93.34%104.94%114.15%88.52%104.71%116.88%107.39%94.58%-
Selling, General & Admin
96.26M119.53M176.63M171.4M179.26M192.93M224.07M262.85M329.33M354.02M
SG&A % of Revenue
60.44%65.94%74.53%76.19%60.97%68.2%71.2%68.54%64.9%-
Research & Development
38.91M49.68M68.31M85.39M101M123.27M138.77M136.43M150.61M162.41M
R&D % of Revenue
24.43%27.4%28.82%37.96%34.35%43.58%44.09%35.58%29.68%-
Other Operating Expenses
5.32M03.75M0-20M-20M5M12.55M00
Operating Income
-2.28M▲ 0%
-13M▼ 470.0%
-50.29M▼ 286.8%
-123.55M▼ 145.7%
-32.87M▲ 73.4%
-82.31M▼ 150.4%
-128.7M▼ 56.4%
-122.37M▲ 4.9%
-86.73M▲ 29.1%
-85.91M▲ 0%
Operating Margin %
-1.43%-7.17%-21.22%-54.92%-11.18%-29.1%-40.89%-31.91%-17.09%-15.58%
Operating Income Growth %
-153.78%-470.01%-286.8%-145.67%73.39%-150.4%-56.35%4.92%29.12%-
EBITDA
3.2M-6.74M-40.43M-88.94M1.55M-46.37M-90.72M-82.44M-44.39M-39.99M
EBITDA Margin %
2.01%-3.72%-17.06%-39.54%0.53%-16.39%-28.83%-21.5%-8.75%-7.25%
EBITDA Growth %
-64.29%-310.5%-500.01%-119.99%101.74%-3093.35%-95.66%9.12%46.16%38.23%
D&A (Non-Cash Add-back)
5.48M6.26M9.86M34.61M34.42M35.95M37.98M39.92M42.34M45.92M
EBIT
1K-12.37M-47.47M-118.2M-35.9M-84.71M-120.09M-135.56M-86.73M-85.91M
Net Interest Income
1.38M2.25M604K-11.74M-12.08M-11.35M-4.47M1.06M6.08M5.47M
Interest Income
1.38M2.25M3.17M2.38M1.29M2.38M9.16M11.11M10.71M10.07M
Interest Expense
002.56M14.12M13.37M13.72M13.63M10.04M4.63M4.6M
Other Income/Expense
2.28M634K256K-8.76M-16.39M-16.12M-5.03M-23.23M-106.31M-108.61M
Pretax Income
1K▲ 0%
-12.37M▼ 1236900.0%
-50.04M▼ 304.6%
-132.31M▼ 164.4%
-49.27M▲ 62.8%
-98.43M▼ 99.8%
-133.73M▼ 35.9%
-145.6M▼ 8.9%
-193.04M▼ 32.6%
-194.52M▲ 0%
Pretax Margin %
0%-6.82%-21.11%-58.82%-16.76%-34.8%-42.49%-37.97%-38.04%-35.28%
Income Tax
93K583K-65.46M-11.97M326K766K934K771K-5.35M-5.19M
Effective Tax Rate %
9300%-4.71%130.83%9.04%-0.66%-0.78%-0.7%-0.53%2.77%2.67%
Net Income
-92K▲ 0%
-12.95M▼ 13977.2%
15.42M▲ 219.1%
-120.35M▼ 880.3%
-49.59M▲ 58.8%
-99.19M▼ 100.0%
-134.66M▼ 35.8%
-146.37M▼ 8.7%
-187.69M▼ 28.2%
-189.33M▲ 0%
Net Margin %
-0.06%-7.14%6.51%-53.5%-16.87%-35.07%-42.79%-38.17%-36.99%-34.34%
Net Income Growth %
-102.03%-13977.17%219.1%-880.26%58.79%-100.02%-35.75%-8.7%-28.23%-53.08%
Net Income (Continuing)
-92K-12.95M15.42M-120.35M-49.59M-99.19M-134.66M-146.37M-187.69M-189.33M
Discontinued Operations
0000000000
Minority Interest
0000000000
EPS (Diluted)
-0.00▲ 0%
-0.37▼ 13603.7%
0.37▲ 200.0%
-2.70▼ 829.7%
-1.07▲ 60.4%
-2.09▼ 95.3%
-2.78▼ 33.0%
-2.77▲ 0.4%
-3.28▼ 18.4%
-3.26▲ 0%
EPS Growth %
-102.25%-200%-829.73%60.37%-95.33%-33.01%0.36%-18.41%-38.4%
EPS (Basic)
-0.00-0.370.41-2.70-1.07-2.09-2.78-2.77-3.28-
Diluted Shares Outstanding
34.38M35.32M41.15M44.5M46.42M47.44M48.43M52.76M57.19M58.02M
Basic Shares Outstanding
34.38M35M37.35M44.5M46.42M47.44M48.43M52.76M57.19M58.02M
Dividend Payout Ratio
----------

GKOS Balance Sheet

Glaukos Corporation (GKOS) balance sheet — assets, liabilities & shareholders' equity

MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Total Current Assets
149.46M176.57M262.88M469.44M486.13M443.86M395.46M449.79M474.98M485.75M
Cash & Short-Term Investments
119.01M140.49M173.98M404.37M414.05M352.69M295.43M318.92M278.76M276.69M
Cash Only
24.51M29.82M62.43M96.6M100.71M119.53M93.47M169.63M90.81M104.25M
Short-Term Investments
94.51M110.67M111.55M307.77M313.34M233.17M201.96M149.29M187.95M172.44M
Accounts Receivable
16.66M18.67M38.42M36.06M33.44M36.07M39.85M60.74M108.61M119.69M
Days Sales Outstanding
38.1737.659.1758.5141.5146.5546.2257.8278.1267.85
Inventory
11.22M13.28M42.58M15.81M23.01M37.84M41.99M57.68M63.56M62.38M
Days Inventory Outstanding
194.59193.34402.7462.91126.06200.23202.78223.9203.11192.13
Other Current Assets
2.57M4.12M013.21M15.63M17.25M18.19M12.46M24.05M26.99M
Total Non-Current Assets
16.38M30.4M555.52M536.06M642.7M630.31M544.95M524.96M418.5M407.57M
Property, Plant & Equipment
11.79M19.15M91.81M95.46M146.13M166.83M174.54M169.94M184.18M182.26M
Fixed Asset Turnover
13.50x9.46x2.58x2.36x2.01x1.70x1.80x2.26x2.76x3.01x
Goodwill
0066.13M66.13M66.13M66.13M66.13M66.13M66.71M66.71M
Intangible Assets
3.15M0382.61M357.69M332.78M307.87M282.96M263.44M141.92M133.03M
Long-Term Investments
08.78M09.57M9.42M7.08M003.83M11.5M
Other Non-Current Assets
1.2M11.04M14.97M7.21M9.11M10.61M21.32M25.45M21.86M25.58M
Total Assets
165.84M▲ 0%
206.97M▲ 24.8%
818.4M▲ 295.4%
1.01B▲ 22.9%
1.13B▲ 12.3%
1.07B▼ 4.8%
940.41M▼ 12.5%
974.76M▲ 3.7%
893.49M▼ 8.3%
893.33M▲ 0%
Asset Turnover
0.96x0.88x0.29x0.22x0.26x0.26x0.33x0.39x0.57x0.58x
Asset Growth %
23.42%24.8%295.42%22.86%12.26%-4.84%-12.45%3.65%-8.34%-0.7%
Total Current Liabilities
26.79M30.36M57.7M49.7M63.36M72.36M74.01M75.13M101.28M89.42M
Accounts Payable
6.24M6.29M5.78M4.37M7.33M14.4M13.44M13.03M24.62M19.15M
Days Payables Outstanding
108.2791.554.6817.3940.1776.2164.9150.5778.6858.41
Short-Term Debt
0001.19M1.01M430K02.47M00
Deferred Revenue (Current)
0000000000
Other Current Liabilities
95K115K13.53M29.6M33.81M35.83M20.59M076.65M70.26M
Current Ratio
5.58x5.81x4.56x9.45x7.67x6.13x5.34x5.99x4.69x5.43x
Quick Ratio
5.16x5.38x3.82x9.13x7.31x5.61x4.78x5.22x4.06x4.73x
Cash Conversion Cycle
124.49139.43407.23104.02127.4170.57184.08231.15202.55201.58
Total Non-Current Liabilities
846K2.75M87.43M288.35M478.32M471.8M404.63M132.7M136.06M132.98M
Long-Term Debt
000189.42M280.03M281.4M282.77M035.77M103.06M
Capital Lease Obligations
0072.63M81.39M102.35M101.08M100.97M103.4M103.88M313.21M
Deferred Tax Liabilities
009.63M10.51M86.45M79.05M7.14M6.93M441K14.71M
Other Non-Current Liabilities
846K2.75M5.17M7.03M9.49M10.28M13.75M22.37M-4.03M29.49M
Total Liabilities
27.63M33.11M145.13M338.05M541.68M544.16M478.65M207.82M237.33M222.4M
Total Debt
0072.63M272M383.38M382.91M383.74M105.87M139.64M103.06M
Net Debt
-24.51M-29.82M10.2M175.4M282.68M263.38M290.27M-63.75M48.83M-1.19M
Debt / Equity
--0.11x0.41x0.65x0.72x0.83x0.14x0.21x0.15x
Debt / EBITDA
----247.50x-----2.58x
Net Debt / EBITDA
-7.66x---182.49x----0.03x
Interest Coverage
---18.51x-8.37x-2.68x-6.17x-8.81x-13.50x-18.71x-18.69x
Total Equity
138.2M▲ 0%
173.86M▲ 25.8%
673.27M▲ 287.2%
667.45M▼ 0.9%
587.15M▼ 12.0%
530M▼ 9.7%
461.77M▼ 12.9%
766.93M▲ 66.1%
656.15M▼ 14.4%
670.93M▲ 0%
Equity Growth %
17.85%25.8%287.25%-0.86%-12.03%-9.73%-12.88%66.09%-14.44%3.52%
Book Value per Share
4.024.9216.3615.0012.6511.179.5314.5411.4711.56
Total Shareholders' Equity
138.2M173.86M673.27M667.45M587.15M530M461.77M766.93M656.15M670.93M
Common Stock
35K36K44K45K47K48K49K56K58K58K
Retained Earnings
-192.18M-205.13M-189.71M-310.06M-365.21M-464.41M-599.07M-745.44M-933.13M-952.91M
Treasury Stock
-132K-132K-132K-132K-132K-132K-132K-132K-132K0
Accumulated OCI
-591K738K1.33M1M15K-2.98M1.17M2.62M3.3M2.64M
Minority Interest
0000000000

GKOS Cash Flow Statement

Glaukos Corporation (GKOS) cash flow — operating, investing & free cash flow history

MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Cash from Operations
25.51M18.86M-369K-22.99M24.71M-33.08M-57.76M-61.32M-46.34M-8.79M
Operating CF Margin %
16.02%10.41%-0.16%-10.22%8.4%-11.7%-18.35%-15.99%-9.13%-
Operating CF Growth %
107.23%-26.05%-101.96%-6129.81%207.48%-233.9%-74.59%-6.16%24.43%1414.81%
Net Income
-92K-12.95M15.42M-120.35M-49.59M-99.19M-134.66M-146.37M-133.66M-189.33M
Depreciation & Amortization
5.48M6.26M9.86M34.61M34.42M35.95M37.98M39.92M38.09M40.59M
Stock-Based Compensation
17.59M25.7M046.48M30.15M38.56M43.53M50.21M63.22M69.38M
Deferred Taxes
-925K1.51M-66.31M-12.18M-1.03M-54K-120K-216K-6.49M-6.48M
Other Non-Cash Items
722K1.92M45.12M31.67M7.19M5.11M5.65M34.62M24.04M53.86M
Working Capital Changes
2.73M-3.58M-4.47M-3.22M3.58M-13.45M-10.13M-39.47M-31.55M23.19M
Change in Receivables
-2.18M-2.25M-6.63M2.24M1.7M-3.14M-3.84M-21.97M-53.02M-53.16M
Change in Inventory
-4.16M-2.3M4.08M1.96M-7.7M-15.47M-4.83M-18.79M2.65M5.14M
Change in Payables
9.23M771K779K-2.68M12.45M7.21M1.3M21K18.82M15.36M
Cash from Investing
-11.73M-26.4M43.43M-205.06M-58.23M44.78M14.1M47.83M-77.61M-30.16M
Capital Expenditures
-6.31M-10.31M-4.72M-6.93M-47.78M-30.27M-20.25M-6.3M-7.67M-9.69M
CapEx % of Revenue
3.96%5.69%1.99%3.08%16.25%10.7%6.43%1.64%1.51%1.76%
Acquisitions
11.7K1.24M49.65M03K151K038K-12.44M-12.44M
Investments
----------
Other Investing
-11.7K-1.24M-1.61M-1.82M-2.08M-1.01M-3.17M-3.15M-22.16M-21.77M
Cash from Financing
4.67M21.58M-9.64M262.54M39.26M6.25M15.04M91.54M11.89M25.7M
Debt Issued (Net)
00-22.5M242.21M-659K-527K-711K51.34M0248K
Equity Issued (Net)
0018.45M24.22M30.94M9.21M19.03M46.76M0-7.04M
Dividends Paid
0000000000
Share Repurchases
0-587K00000000
Other Financing
4.67M21.58M-5.6M-3.89M8.98M-2.43M-3.27M-6.56M11.89M32.5M
Net Change in Cash
18.01M▲ 0%
14.09M▼ 21.8%
32.61M▲ 131.5%
34.17M▲ 4.8%
4.11M▼ 88.0%
18.82M▲ 357.6%
-26.06M▼ 238.5%
76.16M▲ 392.3%
-111.26M▼ 246.1%
-10.9M▲ 0%
Free Cash Flow
19.2M▲ 0%
8.55M▼ 55.5%
-5.09M▼ 159.6%
-29.92M▼ 487.5%
-23.08M▲ 22.9%
-63.35M▼ 174.5%
-78.01M▼ 23.1%
-67.62M▲ 13.3%
-54.01M▲ 20.1%
-18.48M▲ 0%
FCF Margin %
12.05%4.72%-2.15%-13.3%-7.85%-22.4%-24.79%-17.63%-10.64%-3.35%
FCF Growth %
218.31%-55.47%-159.57%-487.53%22.88%-174.51%-23.14%13.32%20.13%65.29%
FCF per Share
0.560.24-0.12-0.67-0.50-1.34-1.61-1.28-0.94-0.32
FCF Conversion (FCF/Net Income)
-277.26x-1.46x-0.02x0.19x-0.50x0.33x0.43x0.42x0.25x0.10x
Interest Paid
0000000000
Taxes Paid
12K401K00000000

GKOS Key Ratios

Glaukos Corporation (GKOS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric201720182019202020212022202320242025TTM
Return on Equity (ROE)
-0.07%-8.3%3.64%-17.95%-7.91%-17.76%-27.16%-23.83%-26.38%-26.46%
Return on Invested Capital (ROIC)
-1.52%-7.57%-9.12%-12.14%-2.88%-7.42%-12.49%-12.61%-9.24%-8.83%
Gross Margin
86.78%86.17%83.72%59.23%77.34%75.61%75.99%75.48%77.49%78.08%
Net Margin
-0.06%-7.14%6.51%-53.5%-16.87%-35.07%-42.79%-38.17%-36.99%-34.34%
Debt / Equity
--0.11x0.41x0.65x0.72x0.83x0.14x0.21x0.15x
Interest Coverage
---18.51x-8.37x-2.68x-6.17x-8.81x-13.50x-18.71x-18.69x
FCF Conversion
-277.26x-1.46x-0.02x0.19x-0.50x0.33x0.43x0.42x0.25x0.10x
Revenue Growth
39.21%13.83%30.73%-5.07%30.7%-3.79%11.26%21.85%32.33%36.3%
Related:GKOS Dividend History·GKOS Revenue History·GKOS Price History·GKOS P/E History·GKOS Financial Ratios·GKOS Institutional Holders

GKOS SEC Filings & Documents

Glaukos Corporation (GKOS) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Apr 29, 2026·SEC

Material company update

Mar 2, 2026·SEC

Material company update

Feb 17, 2026·SEC

10-K Annual Reports

2
FY 2026

Feb 23, 2026·SEC

FY 2025

Feb 25, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

Apr 30, 2026·SEC

FY 2025

Oct 31, 2025·SEC

FY 2025

Aug 4, 2025·SEC

GKOS Frequently Asked Questions

Glaukos Corporation (GKOS) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Glaukos Corporation (GKOS) reported $551.3M in revenue for fiscal year 2025. This represents a 22599% increase from $2.4M in 2012.

Glaukos Corporation (GKOS) grew revenue by 32.3% over the past year. This is strong growth.

Glaukos Corporation (GKOS) reported a net loss of $189.3M for fiscal year 2025.

Dividend & Returns

Glaukos Corporation (GKOS) has a return on equity (ROE) of -26.4%. Negative ROE indicates the company is unprofitable.

Glaukos Corporation (GKOS) had negative free cash flow of $18.5M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in GKOS back in 2012?

Total return calculator · dividends reinvested · 14+ years of data

See returns →

How much would $100/month in GKOS be worth today?

Dollar cost averaging calculator · DCA vs lump sum

Calculate →